Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omeglucosol sodium vs sugammadex for reversal of rocuronium-induced neuromuscular block (Phase II)
CTR20200840Phase 2Completed
- Sponsor
- Zhejiang Xianju Pharmaceutical Co., Ltd.
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of omeglucosol sodium in neuromuscular block (NMB), sponsored by Zhejiang Xianju Pharmaceutical Co., Ltd.. Started May 2020; status: completed.
02
Drugs
omeglucosol sodium
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on CTR20200840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200840.